Nureca Limited announced that its connected health platform, Dr Trust 360, has surpassed 2.4 million registered users. The company also launched Dr Trust Intelligence, an AI-powered analytics suite within the app designed to interpret body-composition data and provide personalized health guidance. This development aims to enhance user understanding of health trends through India-based data infrastructure.

The Dr Trust Intelligence suite analyzes readings from compatible 4-electrode and 8-electrode smart body-composition scales. It offers plain-language interpretation of metrics such as body fat, muscle mass, and visceral fat. The system features automatic detection of meaningful changes and longer-term trends based on user history, along with AI-based diet guidance and actionable recommendations.

Key Capabilities

The new analytics suite focuses on converting raw measurements into actionable insights. Key features include:

• Personalized health analysis to track progress rather than isolated readings.
• Clear reports designed to support informed conversations with healthcare professionals.
• Automatic trend detection based on individual user history.
• AI-guided diet plans aligned with specific health goals.

Saurabh Goyal, Chairman and Managing Director of nureca , stated that the milestone reflects the trust Indian families place in the Dr Trust ecosystem. He emphasized that the combination of intelligent analytics with India-based data infrastructure makes connected preventive healthcare more useful and secure.

Device and Data Infrastructure

Dr Trust's 8-electrode smart scales measure through both hands and feet, offering a detailed view of body composition. Company validation testing indicates up to 98% DEXA-level accuracy for selected metrics, including body fat, muscle mass, and visceral fat. The Dr Trust 360 app integrates compatible devices such as smart body-composition scales, blood pressure monitors, and smart kitchen scales into a single ecosystem.

To ensure data security and compliance, user health data is encrypted and stored on servers located in India. This approach keeps sensitive health records within Indian jurisdiction and aligns with applicable data-protection requirements. Dr Trust Intelligence is available as a premium subscription on Android and iOS platforms.

Nectar Biopharma Private Limited, a member of the promoter group of Nureca Limited , disposed of 60,842 equity shares through an off-market transaction on June 09, 2026. The shares were transferred to promoter Saurabh Goyal for a total consideration of ₹1,43,70,880. This transaction resulted in a re-alignment of shareholding within the promoter and promoter group, while the aggregate holding remained unchanged at 68.09%.

The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Although the filing stated that the disclosure was not strictly required under specific SEBI circulars, it was made as a matter of abundant precaution. The company confirmed that the transaction does not impact the total promoter and promoter group holding in the company.

Shareholding Details

The following table details the changes in shareholding for the promoter and promoter group members following the inter se transfer:

Nishu Kansal, Company Secretary & Compliance Officer of Nureca Limited, signed the disclosure on behalf of the company. Saurabh Goyal, Director, signed the Form C disclosure confirming the transaction details.